Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Lung Cancer Awareness Month Highlights Importance of Preventive Screenings
Advancements in staging and personalized treatments have helped improve lung cancer survival rates, but low […]
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease
AbbVie announced the European Commission (EC) has approved SKYRIZI (risankizumab, 600 mg intravenous [IV] induction and […]
FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes
The U.S. Food and Drug Administration (FDA) has approved Tzield (teplizumab-mzwv), an injection to delay […]
First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy
Telix Pharmaceuticals has announced that a first patient has been dosed in a Phase II […]
Vial Has Added NEXT Oncology, a Global Network of Phase I Cancer Research Centers, to their Preferred Site Network
Vial has added NEXT Oncology to their Preferred Site Network (PSN). Founded by renowned oncologist Dr. Anthony W. […]
CellVax Selects Theragent as Manufacturing Partner for Phase 2 Clinical Trial for Prostate Cancer Immunotherapy
Theragent, a cell therapy Contract Development and Manufacturing Organization (CDMO) focused on advancing next-generation cancer […]
Liverpool Heart and Chest Hospital Selects Clinical Informatics Provider Epro as Digital Partner
Leading healthcare informatics provider Epro has been selected by the Liverpool Heart and Chest Hospital (LHCH) to […]
Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products […]
Olympus Launches THUNDERBEAT Energy Device for Open Surgery
Olympus Corporation (Olympus), a global medtech company committed to making people’s lives healthier, safer, and […]
Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors
Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more